In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

In 2010, Azadeh Dastmalchi's journey toward transforming healthcare began with a personal challenge. Her father's aversion to ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

Health care and tech innovation go hand in hand. From delivering steady streams of medication to speeding up treatment of ...

GE HealthCare’s Portrait Mobile continuous monitoring solution is redefining post-surgical care, according to a new study ...